BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li K, Ouyang L, He M, Luo M, Cai W, Tu Y, Pi R, Liu A. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway. Oncotarget 2017;8:28865-79. [PMID: 28427200 DOI: 10.18632/oncotarget.15868] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Li PC, Tu MJ, Ho PY, Jilek JL, Duan Z, Zhang QY, Yu AX, Yu AM. Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells. Drug Metab Dispos 2018;46:2-10. [PMID: 29061583 DOI: 10.1124/dmd.117.078741] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
2 Shahcheraghi SH, Salemi F, Alam W, Ashworth H, Saso L, Khan H, Lotfi M. The Role of NRF2/KEAP1 Pathway in Glioblastoma: Pharmacological Implications. Med Oncol 2022;39:91. [PMID: 35568790 DOI: 10.1007/s12032-022-01693-0] [Reference Citation Analysis]
3 Sun X, Turcan S. From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas. Cells 2021;10:1225. [PMID: 34067729 DOI: 10.3390/cells10051225] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cano-Galiano A, Oudin A, Fack F, Allega MF, Sumpton D, Martinez-Garcia E, Dittmar G, Hau AC, De Falco A, Herold-Mende C, Bjerkvig R, Meiser J, Tardito S, Niclou SP. Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas. Neurooncol Adv 2021;3:vdab057. [PMID: 34250481 DOI: 10.1093/noajnl/vdab057] [Reference Citation Analysis]
5 Batsios G, Viswanath P, Subramani E, Najac C, Gillespie AM, Santos RD, Molloy AR, Pieper RO, Ronen SM. PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival. Sci Rep 2019;9:10521. [PMID: 31324855 DOI: 10.1038/s41598-019-47021-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
6 Di Gregorio E, Miolo G, Saorin A, Steffan A, Corona G. From Metabolism to Genetics and Vice Versa: The Rising Role of Oncometabolites in Cancer Development and Therapy. Int J Mol Sci 2021;22:5574. [PMID: 34070384 DOI: 10.3390/ijms22115574] [Reference Citation Analysis]
7 Wang J, Quan Y, Lv J, Dong Q, Gong S. LncRNA IDH1-AS1 suppresses cell proliferation and tumor growth in glioma. Biochem Cell Biol 2020;98:556-64. [PMID: 32990028 DOI: 10.1139/bcb-2019-0465] [Reference Citation Analysis]
8 Molenaar RJ, Maciejewski JP, Wilmink JW, van Noorden CJF. Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene 2018;37:1949-60. [PMID: 29367755 DOI: 10.1038/s41388-017-0077-z] [Cited by in Crossref: 97] [Cited by in F6Publishing: 98] [Article Influence: 24.3] [Reference Citation Analysis]
9 Garcia JH, Jain S, Aghi MK. Metabolic Drivers of Invasion in Glioblastoma. Front Cell Dev Biol 2021;9:683276. [PMID: 34277624 DOI: 10.3389/fcell.2021.683276] [Reference Citation Analysis]
10 Kessler J, Hohmann T, Güttler A, Petrenko M, Ostheimer C, Hohmann U, Bache M, Dehghani F, Vordermark D. Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms. Cancers (Basel) 2019;11:E889. [PMID: 31242696 DOI: 10.3390/cancers11060889] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]